Cai L, Chen Y, Tong X, et al. - Researchers examined 7,858 lung cancer samples to determine age‐dependent tendency of genomic changes in lung cancer, as well as to analyze mutational profiles and its link with clinical treatment results in young adenocarcinoma patients. They compared young (≤ 45 years) vs old (> 45 years) patients. They found steady rises in tumor mutation burden as well as changes in a number of genes with age, including KRAS, MET, CDKN2A, PIK3CA and MDM2, while reducing frequencies of ALK, ROS1 and RET fusions, and ERBB2 mutations were seen. Use of EGFR tyrosine kinase inhibitors or chemotherapy as first‐line therapies in EGFR‐positive patients (n = 979) gave rise to similar on‐treatment time between young and old patients. Overall, clinical features as well as genomic attributes of lung cancer in young patients, and particularly in those with adenocarcinoma, were found to be different than those in old patients, and these should be taken into account for therapeutic decision‐making purposes.